ProCE Banner Activity

Phase III TROPION-Lung01: Datopotamab Deruxtecan vs Docetaxel for Previously Treated Advanced or Metastatic NSCLC

Slideset

In the phase III TROPION-Lung01 trial, a PFS benefit was observed with datopotamab deruxtecan vs docetaxel in patients with previously treated advanced or metastatic NSCLC, with the benefit primarily in nonsquamous disease.

Released: October 31, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc